Evenity (Romosozumab) and Benzodiazepines Interaction: What Patients and Clinicians Need to Know

What Is the Interaction Between Romosozumab and Benzodiazepines?

Romosozumab and benzodiazepines do not interact at the metabolic level. Romosozumab is a monoclonal antibody targeting sclerostin, a Wnt-pathway inhibitor secreted by osteocytes. Monoclonal antibodies are not metabolized by cytochrome P450 enzymes or transported by P-glycoprotein; they are cleared through proteolytic catabolism, like endogenous immunoglobulins. Benzodiazepines are small molecules, and while individual agents differ (diazepam is primarily CYP2C19/CYP3A4, lorazepam is glucuronidated), none of those pathways touch romosozumab.

The interaction that matters clinically is pharmacodynamic. Benzodiazepines depress the central nervous system, impairing balance, reaction time, and postural stability. Romosozumab is prescribed precisely to reduce fracture risk. Any medication that increases fall probability works against that therapeutic aim.

Pharmacokinetics of Romosozumab

After two subcutaneous 105 mg injections (for a combined monthly dose of 210 mg), romosozumab reaches peak serum concentration at roughly 5 days. Its half-life is approximately 6.4 days. Clearance is non-linear and concentration-dependent, consistent with target-mediated drug disposition against sclerostin. The FDA-approved prescribing information for romosozumab confirms no formal drug interaction studies are needed from a CYP or transporter standpoint because monoclonal antibodies do not use those pathways (FDA Evenity Prescribing Information).

Pharmacokinetics of Benzodiazepines

The benzodiazepine class spans drugs with very different half-lives and metabolic routes. Triazolam has a half-life of 1.5 to 5.5 hours and relies on CYP3A4. Diazepam has a half-life of 20 to 100 hours and relies on CYP2C19 and CYP3A4. Lorazepam, oxazepam, and temazepam undergo direct glucuronidation, bypassing hepatic CYP. None of these pathways intersect with the proteolytic route used by romosozumab. From a purely kinetic standpoint, co-prescribing is permissible.

Why Benzodiazepines Are Clinically Problematic During Romosozumab Therapy

Treating osteoporosis with romosozumab while leaving a benzodiazepine prescription unaddressed creates a therapeutic contradiction. A bisphosphonate, denosumab, or romosozumab course can increase bone mineral density (BMD) by measurable amounts, but that gain is negated if the patient falls and sustains a hip fracture before it consolidates.

The Quantified Fall Risk

A 2014 meta-analysis published in the British Medical Journal (Donnelly et al., 66 studies, N = 149,000+) found benzodiazepine use associated with an odds ratio of approximately 1.57 for falls in older adults (PubMed PMID: 25325442). A Cochrane systematic review of fall-prevention interventions in older people (Gillespie et al., 2012, updated 2019) identified psychotropic medication withdrawal as one of the few single interventions with evidence of direct fall reduction (Cochrane Library).

Older women, the primary population for romosozumab, are particularly vulnerable. Long-acting benzodiazepines such as diazepam and chlordiazepoxide accumulate with age due to increased volume of distribution and decreased hepatic clearance, extending sedation duration beyond what younger patients experience.

Fracture Risk Amplification

A 2022 study in JAMA Internal Medicine reported that benzodiazepine or Z-drug use was associated with a 40% increased risk of hip fracture in adults older than 65, even after controlling for the underlying anxiety or insomnia diagnosis (PubMed PMID: 36155878). Hip fracture carries a one-year mortality rate of 20 to 30% in older adults and represents a primary outcome that romosozumab is intended to prevent.

The clinical logic becomes direct: prescribing romosozumab at an annual drug cost exceeding $20,000 while leaving a benzodiazepine on the medication list is a clinically inconsistent strategy unless the benzodiazepine cannot be safely discontinued.

Muscle Relaxation and Postural Stability

Beyond sedation, benzodiazepines reduce skeletal muscle tone by potentiating GABA-A receptor activity in the spinal cord and cerebellum. This muscle relaxation compounds gait instability in patients who may already have sarcopenia or peripheral neuropathy. Romosozumab increases bone strength but cannot compensate for impaired neuromuscular control at the moment of a fall.

Romosozumab's Efficacy Data: What Is at Stake

Understanding the magnitude of romosozumab's benefit underscores why protecting that benefit from fall risk matters.

FRAME Trial Results

The phase 3 FRAME trial (N = 7,180 postmenopausal women with osteoporosis, T-score between -2.5 and -3.5 at lumbar spine or total hip) compared romosozumab 210 mg monthly subcutaneous versus placebo for 12 months, followed by 12 months of denosumab in both arms. At 12 months, romosozumab produced a 73% relative risk reduction in new vertebral fracture (P<0.001) and a 36% reduction in clinical fracture versus placebo (NEJM, Cosman et al., 2016). Lumbar spine BMD increased by 13.3% and femoral neck BMD by 6.9% at 12 months.

Those gains represent the expected benefit that benzodiazepine-related falls place in jeopardy.

ARCH Trial Comparator Data

The ARCH trial (N = 4,093) compared romosozumab followed by alendronate versus alendronate alone. Romosozumab-to-alendronate reduced new vertebral fracture risk by 48% relative to alendronate-to-alendronate (P<0.001) and reduced hip fracture risk by 38% (NEJM, Saag et al., 2017). The ARCH trial also revealed the cardiovascular safety signal that now appears as a boxed warning: serious cardiovascular events (MI, stroke) occurred in 2.5% of romosozumab patients versus 1.9% of alendronate patients.

This cardiovascular concern is separate from the benzodiazepine interaction but warrants combined assessment at treatment initiation. Benzodiazepines do not directly worsen the cardiovascular risk, but they can mask exertional symptoms through sedation.

Severity Classification of This Interaction

Drug interaction databases classify the romosozumab-benzodiazepine pairing as a pharmacodynamic interaction of moderate clinical concern, not a contraindication. The FDA label for romosozumab does not list benzodiazepines as a specific contraindication or precaution. The label focuses instead on the cardiovascular boxed warning, hypocalcemia risk, and injection-site reactions.

The HealthRX clinical team uses a three-tier framework for assessing concurrent benzodiazepine use at romosozumab initiation:

Tier 1 (Deprescribe before starting Evenity): Long-acting benzodiazepines (diazepam, chlordiazepoxide, clonazepam) in patients with documented falls or a Timed Up and Go (TUG) test exceeding 12 seconds. Benefit of delaying romosozumab start by 4 to 8 weeks while tapering outweighs the short-term fracture risk window in most stable outpatients.

Tier 2 (Taper concurrently, start Evenity): Short-acting benzodiazepines (lorazepam, oxazepam) used prn at low frequency in patients with no recent falls, TUG <12 seconds, and a clear psychiatric indication. Document a benzodiazepine reduction plan in the chart at the time of the first Evenity injection.

Tier 3 (Continue, increase monitoring): Benzodiazepine cannot be safely tapered due to active seizure disorder or severe refractory anxiety with documented prior taper failure. In this tier, physical therapy referral for balance training, home safety assessment, and six-monthly fall-risk screening are the minimum acceptable additions.

Monitoring Protocol for Patients on Both Agents

Fall Risk Assessment Tools

The Centers for Disease Control and Prevention STEADI (Stopping Elderly Accidents, Deaths, and Injuries) algorithm provides a validated fall-risk screening pathway appropriate for this population (CDC STEADI). The minimum assessment at romosozumab initiation should include:

• A 12-month fall history (falls are predictive of future falls with a positive likelihood ratio of approximately 2.8)
• TUG test (cutoff of 12 seconds for elevated risk)
• 30-second chair stand test
• Four-stage balance test

Repeat assessment at month 6 and at the end of the 12-month romosozumab course.

Hypocalcemia Monitoring

Romosozumab can cause hypocalcemia, particularly in patients with vitamin D deficiency. Hypocalcemia itself increases fall risk through neuromuscular irritability and fatigue. The prescribing information requires calcium and vitamin D supplementation throughout therapy and serum calcium assessment prior to each monthly administration in at-risk patients. Adequate calcium intake (1,000 to 1,200 mg daily from diet plus supplements) and vitamin D (at least 800 IU daily, targeting serum 25-hydroxyvitamin D above 30 ng/mL) are required.

Cardiovascular Screening in the Context of Sedation

Because romosozumab carries a boxed warning for MI and stroke risk, patients with pre-existing cardiovascular disease require careful risk-benefit evaluation. Benzodiazepines can blunt the perception of chest pain or dyspnea through sedation. Clinicians should counsel patients to report any cardiovascular symptoms even if their baseline anxiety is being managed by benzodiazepine therapy.

Patient Counseling Points

Patients starting romosozumab while also taking a benzodiazepine need a direct, plain-language conversation about the competing risks. The following points should be covered at the time of the first injection:

Falls are the enemy of fracture therapy. Romosozumab strengthens bone but takes months to produce full structural effect. A fall during that window, especially at the hip or wrist, can result in a fracture that the therapy was designed to prevent.

Sleepiness is a warning sign. If a benzodiazepine dose produces daytime drowsiness, dizziness on standing, or unsteadiness while walking, the patient should contact the prescribing physician before the next romosozumab injection, not after.

Do not stop benzodiazepines abruptly. Benzodiazepine withdrawal can cause seizures, severe anxiety, and insomnia-driven fatigue. Any taper must be supervised and gradual, typically reducing the dose by 5 to 10% every 1 to 2 weeks using a diazepam equivalent conversion to standardize the taper.

Alcohol compounds the risk. Alcohol and benzodiazepines both depress the CNS, and their combination amplifies fall risk synergistically. Patients on romosozumab who are also using benzodiazepines should be explicitly counseled to avoid alcohol.

Injection site reactions are distinct from CNS symptoms. Romosozumab causes mild injection-site reactions (pain, erythema, swelling) in approximately 18% of patients per the FDA label. These are local and transient. Central symptoms such as dizziness or confusion in a patient on benzodiazepines should prompt a medication review, not attribution to the injection.

Special Populations

Patients Over 75

Women over 75 represent the highest-risk subgroup for both osteoporotic fracture and benzodiazepine-related falls. The American Geriatrics Society Beers Criteria explicitly list all benzodiazepines as "Avoid" in older adults due to increased sensitivity to CNS effects (AGS Beers Criteria 2023). In this group, the threshold for Tier 1 deprescribing should be lower than in younger postmenopausal patients.

Patients with Renal Impairment

Romosozumab has not been studied in patients with severe renal impairment (eGFR <30 mL/min/1.73 m2). Renal impairment increases the risk of hypocalcemia from romosozumab and may reduce benzodiazepine clearance (particularly for renally excreted metabolites), compounding sedation. This combination warrants nephrology or clinical pharmacology consultation.

Patients with Prior Stroke or TIA

The romosozumab cardiovascular boxed warning is most relevant in patients with a history of MI, stroke, or TIA within the preceding year. Many such patients are prescribed benzodiazepines for post-stroke anxiety or sleep disruption. In this subgroup, romosozumab is generally not recommended per the FDA label unless no other option is clinically viable.

Deprescribing Benzodiazepines: Practical Guidance

The Endocrine Society's 2020 clinical practice guideline on osteoporosis in postmenopausal women does not address benzodiazepine co-prescribing directly, but states: "Clinicians should address all modifiable contributors to fracture risk, including fall risk factors, as part of a complete osteoporosis management plan." (Endocrine Society Guideline)

Benzodiazepine deprescribing resources supported by evidence include the Ashton Manual taper schedule and NEJM-published guidance on tapering in primary care settings. A 2018 systematic review in Annals of Internal Medicine (Guina and Merrill, PMID 29480279) found that structured gradual taper with behavioral support achieved cessation in 40 to 80% of long-term benzodiazepine users within 6 months, with cognitive-behavioral therapy for insomnia (CBT-I) significantly improving success rates (PubMed PMID: 29480279).

Non-benzodiazepine alternatives for common indications:

• Insomnia: CBT-I (first-line per American Academy of Sleep Medicine), low-dose doxepin 3 to 6 mg, or melatonin receptor agonists (ramelteon 8 mg)
• Anxiety: SSRIs (sertraline, escitalopram), SNRIs (venlafaxine), or buspirone; none carry significant fall risk
• Muscle spasm: Cyclobenzaprine has its own fall risk, but topical diclofenac or physical therapy may serve selected patients without CNS depression

Switching to an alternative before romosozumab initiation reduces the competing-risk problem to near zero from a pharmacodynamic standpoint.

Summary of Clinical Decision Points

Romosozumab and benzodiazepines can technically be co-prescribed. The absence of a CYP or P-gp interaction means no dose adjustment to either drug is required on pharmacokinetic grounds. The clinical challenge is entirely pharmacodynamic: sedation increases falls, falls cause fractures, and fractures are the precise outcome romosozumab is prescribed to prevent.

At the time of every romosozumab prescription, the treating clinician should review the full medication list for sedating agents, apply the STEADI fall-risk algorithm, document a benzodiazepine management plan, ensure adequate calcium and vitamin D supplementation, and screen for cardiovascular contraindications per the boxed warning. Patients with a TUG time exceeding 12 seconds who are on any long-acting benzodiazepine should complete a supervised taper before the first romosozumab injection is administered.